Tyrosine-protein kinase CSK

(Redirected from Sarcoma inducing gene)

Tyrosine-protein kinase CSK also known as C-terminal Src kinase is an enzyme that, in humans, is encoded by the CSK gene.[5] This enzyme phosphorylates tyrosine residues located in the C-terminal end of Src-family kinases (SFKs) including SRC, HCK, FYN, LCK, LYN and YES1.[6][7]

CSK
Available structures
PDBOrtholog search: H3BU69 PDBe H3BU69 RCSB
Identifiers
AliasesCSK, Src, c-src tyrosine kinase, CSK/Src, non-receptor tyrosine kinase, C-terminal Src kinase
External IDsOMIM: 190090, 124095; MGI: 88537; HomoloGene: 55818; GeneCards: CSK; OMA:CSK - orthologs
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_001127190
NM_004383
NM_001354988

NM_007783
NM_001304761

RefSeq (protein)

NP_001120662
NP_004374
NP_001341917

NP_001291690
NP_031809

Location (UCSC)Chr 15: 74.78 – 74.8 MbChr 9: 57.53 – 57.56 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Function

edit

This Non-receptor tyrosine-protein kinase plays an important role in the regulation of cell growth, differentiation, migration and immune response. CSK acts by suppressing the activity of the Src family of protein kinases by phosphorylation of Src family members at a conserved C-terminal tail site in Src.[8][9][10][11] Upon phosphorylation by other kinases, Src-family members engage in intramolecular interactions between the phosphotyrosine tail and the SH2 domain that result in an inactive conformation. To inhibit SFKs, CSK is then recruited to the plasma membrane via binding to transmembrane proteins or adapter proteins located near the plasma membrane and ultimately suppresses signaling through various surface receptors, including T-cell receptor (TCR) and B-cell receptor (BCR) by phosphorylating and maintaining inactive several effector molecules.[6][7]

Role in development and regulation

edit

Tyrosine-protein kinase CSK is involved in the following developmental, metabolic, and signal transduction cascades:

Adherens junction organization, blood coagulation, brain development, cell differentiation, cell migration, cellular response to peptide hormone stimulus, central nervous system development, epidermal growth factor receptor signaling pathway, innate immune response, epithelium morphogenesis, regulation of bone resorption, negative regulation of cell proliferation, negative regulation of ERK1 and ERK2 cascade, negative regulation of Golgi to plasma membrane protein transport, negative regulation of interleukin-6 production, negative regulation of kinase activity, negative regulation of low-density lipoprotein particle clearance, negative regulation of phagocytosis, dendrocyte differentiation, peptidyl-tyrosine autophosphorylation, platelet activation, positive regulation of MAP kinase activity, regulation of cell proliferation, regulation of cytokine production, regulation of Fc receptor mediated stimulatory signaling pathway, T cell costimulation, T cell receptor signaling pathway.[12]

Expression and subcellular location

edit

CSK is expressed in the lungs and macrophages as well as several other tissues.[13] Tyrosine-Kinase CSK is mainly present in the cytoplasm, but also found in lipid rafts making cell-cell junction.[12]

Mutations

edit

Clinical significance

edit

Csk's interaction with a phosphatase ("Lyp", gene product of PTPN22) is possibly associated with the increased autoimmune diseases associated with PTPN22 mutations.[16]

References

edit
  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000103653Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000032312Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ "Entrez Gene: C-src tyrosine kinase". Retrieved 2013-07-11.
  6. ^ a b Bergman M, Mustelin T, Oetken C, Partanen J, Flint NA, Amrein KE, Autero M, Burn P, Alitalo K (Aug 1992). "The human p50csk tyrosine kinase phosphorylates p56lck at Tyr-505 and down regulates its catalytic activity". The EMBO Journal. 11 (8): 2919–24. doi:10.1002/j.1460-2075.1992.tb05361.x. PMC 556773. PMID 1639064.
  7. ^ a b Sun G, Budde RJ (Sep 1997). "Expression, purification, and initial characterization of human Yes protein tyrosine kinase from a bacterial expression system". Archives of Biochemistry and Biophysics. 345 (1): 135–42. doi:10.1006/abbi.1997.0236. PMID 9281320.
  8. ^ Nada S, Okada M, MacAuley A, Cooper JA, Nakagawa H (May 1991). "Cloning of a complementary DNA for a protein-tyrosine kinase that specifically phosphorylates a negative regulatory site of p60c-src". Nature. 351 (6321): 69–72. Bibcode:1991Natur.351...69N. doi:10.1038/351069a0. PMID 1709258. S2CID 4363527.
  9. ^ Nada S, Yagi T, Takeda H, Tokunaga T, Nakagawa H, Ikawa Y, Okada M, Aizawa S (Jun 1993). "Constitutive activation of Src family kinases in mouse embryos that lack Csk". Cell. 73 (6): 1125–35. doi:10.1016/0092-8674(93)90642-4. PMID 8513497. S2CID 37988394.
  10. ^ Chong YP, Chan AS, Chan KC, Williamson NA, Lerner EC, Smithgall TE, Bjorge JD, Fujita DJ, Purcell AW, Scholz G, Mulhern TD, Cheng HC (Nov 2006). "C-terminal Src kinase-homologous kinase (CHK), a unique inhibitor inactivating multiple active conformations of Src family tyrosine kinases". The Journal of Biological Chemistry. 281 (44): 32988–99. doi:10.1074/jbc.M602951200. PMC 4281726. PMID 16959780.
  11. ^ Chong YP, Mulhern TD, Cheng HC (Sep 2005). "C-terminal Src kinase (CSK) and CSK-homologous kinase (CHK)--endogenous negative regulators of Src-family protein kinases". Growth Factors. 23 (3): 233–44. doi:10.1080/08977190500178877. PMID 16243715. S2CID 38227036.
  12. ^ a b Universal protein resource accession number P41240 for "Tyrosine-protein kinase CSK" at UniProt.
  13. ^ Bräuninger A, Holtrich U, Strebhardt K, Rübsamen-Waigmann H (Jan 1992). "Isolation and characterization of a human gene that encodes a new subclass of protein tyrosine kinases". Gene. 110 (2): 205–11. doi:10.1016/0378-1119(92)90649-a. PMID 1371489.
  14. ^ a b Joukov V, Vihinen M, Vainikka S, Sowadski JM, Alitalo K, Bergman M (Mar 1997). "Identification of csk tyrosine phosphorylation sites and a tyrosine residue important for kinase domain structure". The Biochemical Journal. 322 (3): 927–35. doi:10.1042/bj3220927. PMC 1218276. PMID 9148770.
  15. ^ Vang T, Torgersen KM, Sundvold V, Saxena M, Levy FO, Skålhegg BS, Hansson V, Mustelin T, Taskén K (Feb 2001). "Activation of the COOH-terminal Src kinase (Csk) by cAMP-dependent protein kinase inhibits signaling through the T cell receptor". The Journal of Experimental Medicine. 193 (4): 497–507. doi:10.1084/jem.193.4.497. PMC 2195911. PMID 11181701.
  16. ^ Fiorillo E, Orrú V, Stanford SM, Liu Y, Salek M, Rapini N, Schenone AD, Saccucci P, Delogu LG, Angelini F, Manca Bitti ML, Schmedt C, Chan AC, Acuto O, Bottini N (Aug 2010). "Autoimmune-associated PTPN22 R620W variation reduces phosphorylation of lymphoid phosphatase on an inhibitory tyrosine residue". The Journal of Biological Chemistry. 285 (34): 26506–18. doi:10.1074/jbc.M110.111104. PMC 2924087. PMID 20538612.
edit